
The FDA is requiring new labeling across all GLP-1 receptor agonists to warn of a potential increased risk of a rare, vision-threatening optic nerve condition.
Catch up on any of the neurology news headlines you may have missed in December 2025, compiled into 1 place by the NeurologyLive® team.
The FDA was busy in December 2025, making a number of decisions on potential new therapeutic agents, including accepting a new drug application, clearing the initiation of a clinical trial, granting an approval, pushing back a review, and expanding an indication.





